Management of the febrile neutropenic patient with cancer

Rasim A. Gucalp, H. W. Grunwald

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Infection remains the most serious complication of intensive anticancer therapy, particularly in patients with hematologic malignancies. The spectrum of organisms responsible for these infections in neutropenic cancer patients has changed markedly during the last three decades. In most centers, gram-positive cocci have become the most common isolates. The development of broad-spectrum antibiotics has prevented early death from bacterial infections in these patients. As the duration of neutropenia becomes more protracted, the likelihood of invasive fungal infection with candida and aspergillus increases. Encouraging new developments include innovative methods for delivery of amphotericin B and new antifungal agents such as fluconazole in the treatment of invasive fungal infections in these critically ill patients.

Original languageEnglish (US)
Pages (from-to)137-148
Number of pages12
JournalOncology
Volume5
Issue number7
StatePublished - 1991

Fingerprint

Fever
Neoplasms
Gram-Positive Cocci
Fluconazole
Antifungal Agents
Amphotericin B
Hematologic Neoplasms
Aspergillus
Infection
Neutropenia
Candida
Bacterial Infections
Critical Illness
Anti-Bacterial Agents
Therapeutics
Invasive Fungal Infections

ASJC Scopus subject areas

  • Oncology

Cite this

Management of the febrile neutropenic patient with cancer. / Gucalp, Rasim A.; Grunwald, H. W.

In: Oncology, Vol. 5, No. 7, 1991, p. 137-148.

Research output: Contribution to journalArticle

Gucalp, RA & Grunwald, HW 1991, 'Management of the febrile neutropenic patient with cancer', Oncology, vol. 5, no. 7, pp. 137-148.
Gucalp, Rasim A. ; Grunwald, H. W. / Management of the febrile neutropenic patient with cancer. In: Oncology. 1991 ; Vol. 5, No. 7. pp. 137-148.
@article{c926be28843d420d9098d8d027cd5e71,
title = "Management of the febrile neutropenic patient with cancer",
abstract = "Infection remains the most serious complication of intensive anticancer therapy, particularly in patients with hematologic malignancies. The spectrum of organisms responsible for these infections in neutropenic cancer patients has changed markedly during the last three decades. In most centers, gram-positive cocci have become the most common isolates. The development of broad-spectrum antibiotics has prevented early death from bacterial infections in these patients. As the duration of neutropenia becomes more protracted, the likelihood of invasive fungal infection with candida and aspergillus increases. Encouraging new developments include innovative methods for delivery of amphotericin B and new antifungal agents such as fluconazole in the treatment of invasive fungal infections in these critically ill patients.",
author = "Gucalp, {Rasim A.} and Grunwald, {H. W.}",
year = "1991",
language = "English (US)",
volume = "5",
pages = "137--148",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "7",

}

TY - JOUR

T1 - Management of the febrile neutropenic patient with cancer

AU - Gucalp, Rasim A.

AU - Grunwald, H. W.

PY - 1991

Y1 - 1991

N2 - Infection remains the most serious complication of intensive anticancer therapy, particularly in patients with hematologic malignancies. The spectrum of organisms responsible for these infections in neutropenic cancer patients has changed markedly during the last three decades. In most centers, gram-positive cocci have become the most common isolates. The development of broad-spectrum antibiotics has prevented early death from bacterial infections in these patients. As the duration of neutropenia becomes more protracted, the likelihood of invasive fungal infection with candida and aspergillus increases. Encouraging new developments include innovative methods for delivery of amphotericin B and new antifungal agents such as fluconazole in the treatment of invasive fungal infections in these critically ill patients.

AB - Infection remains the most serious complication of intensive anticancer therapy, particularly in patients with hematologic malignancies. The spectrum of organisms responsible for these infections in neutropenic cancer patients has changed markedly during the last three decades. In most centers, gram-positive cocci have become the most common isolates. The development of broad-spectrum antibiotics has prevented early death from bacterial infections in these patients. As the duration of neutropenia becomes more protracted, the likelihood of invasive fungal infection with candida and aspergillus increases. Encouraging new developments include innovative methods for delivery of amphotericin B and new antifungal agents such as fluconazole in the treatment of invasive fungal infections in these critically ill patients.

UR - http://www.scopus.com/inward/record.url?scp=0025826318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025826318&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 137

EP - 148

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 7

ER -